Product nameActive human XIAP peptide
See all XIAP proteins and peptides
Amino Acid Sequence
Our Abpromise guarantee covers the use of ab41843 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Preservative: 0.02% Sodium Azide
Constituents: 0.1% BSA, PBS, pH 7.2
This product is an active protein and may elicit a biological response in vivo, handle with caution.
- AP 13
- Apoptosis Inhibitor 3
FunctionApoptotic suppressor. Has E3 ubiquitin-protein ligase activity. Mediates the proteasomal degradation of target proteins, such as caspase-3, SMAC or AIFM1. Inhibitor of caspase-3, -7 and -9. Mediates activation of MAP3K7/TAK1, leading to the activation of NF-kappa-B.
Tissue specificityUbiquitous, except peripheral blood leukocytes.
Involvement in diseaseDefects in XIAP are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2) [MIM:300635]. XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma.
Sequence similaritiesBelongs to the IAP family.
Contains 3 BIR repeats.
Contains 1 RING-type zinc finger.
DomainThe first BIR domain is involved in interaction with TAB1/MAP3K7IP1 and is important for dimerization. The second BIR domain is sufficient to inhibit caspase-3 and caspase-7, while the third BIR is involved in caspase-9 inhibition. The interactions with SMAC and PRSS25 are mediated by the second and third BIR domains.
modificationsUbiquitinated and degraded by the proteasome in apoptotic cells.
Phosphorylation by PKB/AKT protects XIAP against ubiquitination and protects the protein against proteasomal degradation.
- Information by UniProt
ab41843 has not yet been referenced specifically in any publications.